MAX BioPharma Revenue and Competitors
Estimated Revenue & Valuation
- MAX BioPharma's estimated annual revenue is currently $2.3M per year.
- MAX BioPharma's estimated revenue per employee is $155,000
Employee Data
- MAX BioPharma has 15 Employees.
- MAX BioPharma grew their employee count by 25% last year.
MAX BioPharma's People
Name | Title | Email/Phone |
---|---|---|
1 | Director Finance & Operations | Reveal Email/Phone |
2 | Associate Strategic Partnerships and PR | Reveal Email/Phone |
MAX BioPharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is MAX BioPharma?
MAX BioPharma is a California-based biotechnology firm developing novel small molecule lipids, referred to as oxysterols, as candidates for therapeutic drugs for debilitating and fatal human diseases. These oxysterol molecules belong to the family of sterols that have the ability to stimulate bone growth, block the growth of cancer cells, and inhibit their ability to metastasize. The company is a pioneer in this new field of Oxysterol Therapeutics® and focused on translating our key science into use for two large unmet medical needs: bone formation (in fracture repair, bone tissue engineering, and osteoporosis) and cancer.
keywords:N/AN/A
Total Funding
15
Number of Employees
$2.3M
Revenue (est)
25%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.3M | 15 | 7% | N/A |
#2 | $2M | 15 | -48% | N/A |
#3 | N/A | 15 | 7% | N/A |
#4 | $3.2M | 15 | -6% | N/A |
#5 | $0.7M | 15 | 36% | N/A |